GlassScriptPhysician profile
Bridget R Starner
NPI 1659848794
$4,593.21
in general payments reported to CMS, 2019-2025
37 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $226 · 2022: $546 · 2023: $1,605 · 2024: $1,056 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,821.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $780.23 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $434.89 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $364.65 | 2022-2023 | Breztri, Farxiga, Airsupra |
| Myriad Women'S Health, INC. | $314.37 | 2023 | Myrisk |
| Exact Sciences Corporation | $306.47 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $244.61 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $232.13 | 2022-2025 | |
| Amgen INC. | $205.44 | 2022-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $183.27 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.72 | 2022-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Boston Scientific Corporation | $139.80 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $115.37 | 2022-2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $108.49 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $93.10 | 2024-2025 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $93.06 | 2025 | Dupixent |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $82.18 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $78.12 | 2022-2025 | |
| Edwards Lifesciences Corporation | $64.80 | 2023-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.26 | 2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $61.20 | 2022-2025 | Camzyos, Eliquis |
| Otsuka America Pharmaceutical, INC. | $59.08 | 2023-2024 | Rexulti |
| Therapeuticsmd, INC. | $46.67 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.14 | 2022 | |
| Janssen Pharmaceuticals, INC | $41.84 | 2023 | Spravato |
| Merck Sharp & Dohme LLC | $38.33 | 2022-2024 | Gardasil 9, Capvaxive, Gardasil |
| Madrigal Pharmaceuticals | $30.61 | 2025 | Rezdiffra |
| Abbott Laboratories | $22.53 | 2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $22.45 | 2022 | |
| Horizon Therapeutics Plc | $20.79 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $20.28 | 2022 | |
| Organon LLC | $18.53 | 2021 | |
| Insulet Corporation | $16.33 | 2025 | Omnipod |
| Seqirus USA INC | $15.63 | 2025 | Fluad, Flucelvax |
| Grifols USA, LLC | $14.91 | 2025 | Prolastin-C Liquid |
| Ibsa Pharma INC. | $14.32 | 2025 | Flector, Licart, Tirosint |
| Amarin Pharma, INC. | $13.83 | 2023 | |
| Sanofi-Aventis U.S. LLC | $13.78 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Starner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.